GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to partner with other Big Pharma names?

Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Novo Nordisk (NYSE: NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced ...

Investing.com -- Novo Nordisk A/S (NYSE: NVO) stock dropped 2.1% premarket following news that Spain’s health ministry has requested clarification about the company’s obesity awareness campaign, which ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake ...